SIAIS056
SIAIS056 is a BCR-ABL PROTAC degrader with a DC50 value of 0.18 nM. SIAIS056 time-dependently inhibits the BCR-ABL signaling pathway, accompanied by decreased phosphorylation of BCR-ABL and the downstream molecules STAT5 and CRKL in K562 cells. SIAIS056 induces the degradation of several clinically relevant resistance-conferring mutations of BCR-ABL. SIAIS056 exhibits anti-proliferative activity and induces substantial tumor regression in K562 xenograft models. SIAIS056 can be used for leukemia research.
(Pink: Bcr-Abl ligand (HY-175916); Blue: Cereblon ligand (HY-W586107); Black: linker (HY-41939)).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2378581-37-2
- Formule: C35H34ClN9O5S2
- Masse moléculaire:760.28
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform PROTACs
More
Activité biologique
Description
IC50 & Target
[1]|
Bcr-Abl 0.18 μM (DC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| K562 | IC50 |
0.49 nM
Compound: 17; SIAIS056
|
Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay
Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by CCK8 assay
|
[PMID: 34217059] |
In Vitro
SIAIS056 (2 days) reduces anti-proliferative activity against K562 and 32D-BCR-ABL cells[1].
SIAIS056 (0-100 μM, 0-24 h) time-dependently inhibits the BCR-ABL signaling pathway, accompanied by decreased phosphorylation of BCR-ABL and its downstream molecules STAT5 and CRKL in K562 cells[1].
SIAIS056 (0-300 nM, 16 h) exerts the ability to overcome resistance to clinical tyrosine kinase inhibitors caused by (or associated with) the majority of clinically common BCR-ABL mutations in murine myeloid cell line 32D (including BCR-ABL-WT, BCR-ABL-G250E, BCR-ABL-E255V, BCR-ABL-V299L, BCR-ABL-F317L, BCR-ABL-F317V, BCR-ABL-T315A)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:K562 cells
-
Concentration:0, 1, 3, 10, 30 and 100 nM
-
Incubation Time:0, 2, 4, 8, 12, 18 and 24 h
-
Result:Dramatically decreased the protein level of BCR-ABL and c-ABL at dose dependent manner (16 h) and time dependent manner (30 nM).
Induced the degradation of Src, but not PDGFRβ.
Dramatically decreased BCR-ABL after4h treatment at the 30 nM.
Time-Dependently inhibited the BCR-ABL signaling accompanied with decreased phosphorylation of BCR ABL and the downstream molecules STAT5 and CRKL.
Induced degradation of BCR-ABL and c-ABL at 30 nM for 8 h, which was significantly blocked by Pomalidomide (HY-10984) (4 μM, 2 h), Dasatinib (HY-10181) (100 nM, 2 h), MG132 (HY-13259) (2 μM, 2 h), Pevonedistat (HY-70062) (3 μM, 2 h).
-
Cell Line:K562 cells
-
Concentration:0, 10, 100 and 300 nM
-
Incubation Time:16 h
-
Result:Induced degradation of BCR-ABL mutations in BCR-ABL-WT, BCR-ABL-G250E, BCR-ABL-E255V, BCR-ABL-V299L, BCR-ABL-F317L, BCR-ABL-F317V and BCR-ABL-T315A, but in BCR-ABL-T3151 cells.
Parmacokinetics
| Species | Dose | Route | T1/2 | Tmax | Cmax | AUC0-t | MRT0-t | Vss | Vz | CL |
|---|---|---|---|---|---|---|---|---|---|---|
| Rat[1] | 2 mg/mL | i.v. | 4.23 h | 0.08 h | 1497.45 ng/mL | 926.29 ng·h/mL | 2 h | 5225.18 mL/kg | 13048.83 mL/kg | 2140.26 mL/h/kg |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:K562 cells (2 x 106) induced-NOD/SCID mouse[1]
-
Dosage:1, 3 and 10 mg/kg
-
Administration:i.p., once a day for 10 days
-
Result:Observed a reduction in tumor burden at 1 mg/kg.
Induced complete tumor regression at 10 mg/kg, which was maintained even after drug withdrawal.
Showed tumor growth inhibition (TGI) values of 78.9%, 93.8%, and 98.8% for the 1, 3, and 10 mg/kg.
exhibited similar anti-leukemic activity at 3 mg/kg to that of Dasatinib (HY-10181) at 5 mg/kg (o.p.) (TGI: 93.8% versus 95.1%).
Showed well tolerate at the dose of 100 mg/kg.
Preserved the weight.
Showsed an anti-CML efficacy after 10 days.
Observed the BCR-ABL protein degradation at 4 day as well as suppression of BCR-ABL phosphorylation.
Chemical Information
-
CAS No. 2378581-37-2
-
Masse moléculaire 760.28
-
Formule C35H34ClN9O5S2
-
SMILES
O=C(C1=CN=C(NC2=CC(N3CCN(CC3)CCSC4=CC=CC(C(N5C6C(NC(CC6)=O)=O)=O)=C4C5=O)=NC(C)=N2)S1)NC7=C(C)C=CC=C7Cl
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
Pureté et documentation
Références
[1]. Chen X, et al. Mighty mini-PROTACs: an emerging class of degraders. Eur J Med Chem. 2026 Jan 5;301:118202. [Content Brief]
[2]. Kang CH, et al. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC). Biochem Biophys Res Commun. 2018 Oct 28;505(2):542-547. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)